Physician profile
Patrick S Antoun
NPI 1184884850
$2,069.18
in general payments reported to CMS, 2019-2025
29 companies · $22.58 in 2025
The $22.58 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,436 · 2020: $49.58 · 2021: $96.33 · 2022: $250 · 2023: $215 · 2025: $22.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $279.19 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $230.28 | 2019-2022 | |
| Amgen INC. | $217.21 | 2019 | |
| Bard Peripheral Vascular, INC. | $166.59 | 2019 | |
| Boston Scientific Corporation | $163.44 | 2019-2021 | |
| Abiomed | $145.14 | 2019-2025 | |
| Edwards Lifesciences Corporation | $143.37 | 2019-2020 | |
| Cardiovascular Systems INC. | $114.05 | 2019-2021 | |
| Gilead Sciences, INC. | $80.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $63.00 | 2019 | |
| Astellas Pharma US INC | $57.06 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.21 | 2019 | |
| Shockwave Medical, INC | $46.28 | 2020-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Braemar Manufacturing, LLC | $40.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.43 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $29.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.13 | 2019-2023 | |
| Endologix LLC | $20.89 | 2021 | |
| Chiesi USA, INC. | $18.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.18 | 2019 | |
| Ge Healthcare | $16.59 | 2021 | |
| Amarin Pharma, INC. | $15.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.60 | 2019 | |
| Ekos Corporation | $15.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.18 | 2019 | |
| Terumo Medical Corporation | $14.12 | 2019 | |
| Pfizer INC. | $12.38 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Antoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.